NCT01579084View on ClinicalTrials.gov

Safety and Tolerability of AGN-199201 in Patients With Erythema Associated With Rosacea

PHASE1CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

June 30, 2012

Study Completion Date

June 30, 2012

Conditions
RosaceaErythema
Interventions
DRUG

AGN-199201 Formulation A

AGN-199201 Formulation A applied to the face as per protocol twice daily.

DRUG

AGN-199201 Formulation B

AGN-199201 Formulation B applied to the face as per protocol twice daily.

DRUG

AGN-199201 Formulation C

AGN-199201 Formulation C applied to the face as per protocol twice daily.

DRUG

AGN-199201 Vehicle

AGN-199201 vehicle (placebo) applied to the face as per protocol twice daily.

Trial Locations (1)

Unknown

Austin

Sponsors

Lead Sponsor

Allergan
All Listed Sponsors
lead

Allergan

INDUSTRY

NCT01579084 - Safety and Tolerability of AGN-199201 in Patients With Erythema Associated With Rosacea | Biotech Hunter | Biotech Hunter